Dr. Ehrhardt is a biophysicist with a Ph.D. in human physiology. Throughout her career, she focused on driving biomedical research through efficient application of innovative technologies and strategies. She built and led successful teams in industry, including at Merck, where she headed a laboratory providing leading technologies for cell-based research from early discovery through manufacturing; and at BMS where Dr. Ehrhardt led and grew an international clinical assay team to robustly cover large scale registrational and translational clinical analysis generating clinical decision-driving data and mechanistic insights for immuno-oncology, cardiovascular, immunology, metabolic and rare disease studies. Before returning to Merck, Dr. Ehrhardt fulfilled one of her scientific aspirations at CHDI Foundation, designing and implementing successful clinical biomarker discovery and development strategies for Huntington’s disease. Currently, at Merck, Dr. Ehrhardt is providing strategic and technical leadership for the development and implementation of industry-leading and QC-friendly cell-based assays and models for potency determination that reflect the unique mechanisms of biologics products in clinical studies and beyond.
Ning is a bioinformatics scientist at Arcus Biosciences, where he is responsible for drug discovery, target identification, and indication prioritization in multiple immune-oncology drug programs. Notably, Ning pioneered the 3D organoids based drug response prediction technology, which largely facilitated cancer model selection. During his PhD, he studied with Professor Alexander Hoffmann at UCLA, where he built up computational framework to identify synergy between key immune response signaling pathways in macrophage. Ning holds a PhD in Bioinformatics from UCLA.
Ryan Kelly is an Associate Professor in the Department of Chemistry and Biochemistry at Brigham Young University (BYU). He received his Ph.D. in analytical chemistry in 2005 from BYU and spent the next 13 years at Pacific Northwest National Laboratory where he began as a postdoc and ultimately served as Chief Technologist for EMSL, a national scientific user facility, before returning to academia in 2018. In 2020, he founded MicrOmics Technologies LLC, a startup focused on developing and disseminating ultrasensitive mass spectrometry solutions.
A central theme of Dr. Kelly’s research has been the development of new technological solutions for improved biochemical analyses, including mass spectrometry-based omics. Dr. Kelly has authored or coauthored more than 100 publications and is a named inventor on 14 issued and pending patents, several of which have been licensed and commercialized. His work has been recognized with several awards including two R&D 100 awards, a Federal Laboratory Consortium Award for Excellence in Technology Transfer and the Georges Guiochon HPLC Faculty Fellowship.
Dr Catherine Alix-Panabières received her PhD degree in 1998 at the Institute of Virology in Strasbourg-France. Dr Catherine Alix-Panabières & Prof Pantel coined for the first time the term ‘Liquid Biopsy’in 2010 (Trends Mol Med).
As an associate professor, she became the new director of the Laboratory of Rare Human Circulating Cells (LCCRH) at the UMC of Montpellier. In this unique platform, they isolate, detect and characterize CTCs using different technologies. She has authored >100 scientific publications in this field during the last years and 10 book chapters; she is the inventor of three patents in the liquid biopsy field and she is part of EU and national projects. It was a great honor for her to receive the Gallet et Breton Cancer Prize, the highest honor conferred by the French Academy of Medicine in November 2012 and, the 2017 AACR Awardfor the most cited scientific article in 2015 (Cayrefourcq et al. Cancer Res).
Dr. Cátia Moutinho is a group Leader at the Garvan-Weizmann Centre for Cellular Genomics, at the Garvan Institute. Her team focuses on single-cell genomics development. She is a biologist by training, with a PhD in Biomedicine and a master’s in clinical Trials and Medical Affairs. She has an extensive experience in the wet-lab, with a strong background in single-cell technology, as well as cancer genetics and epigenetics. She has more than 45 scientific publications in peer-reviewed journals including original papers and a book chapter. After starting her professional career in Oporto, Portugal, and working in Madrid and Barcelona for more than 10 years, she decided to embark on a new journey in Sydney, Australia, where she is currently residing.
Dr. Yue Wang is a Technical Application Liaison at Mission Bio. She works with academic researchers, industrial leaders and distributors to employ Tapestri multi-omics tool to accelerate their researches and drug development workflow. She obtained her Ph.D. in molecular virology with a certificate in bioinformatics at University of Delaware. Her project had a focus on development of RNAi molecules to inhibit influenza virus replication. Before joining Mission Bio in 2020, she worked at GENEWIZ as a field application scientist, consulting customers on various NGS bulk sequencing services and also single cell sequencing technologies.
John Bashkin is a co-founder and Chief Strategy Officer for S2 Genomics. He has 30 years’ experience leading innovation programs and business development in life sciences. He previously held senior positions at Molecular Dynamics, where he led the development of the MegaBACE 1000 96-capillary sequencing system, Amersham, and SRI International. He received his Ph.D. in Chemistry from Indiana University and an MBA from Santa Clara University.
Sébastien is Product Manager for cellenONE and spheroONE, Cellenion’s flagship instruments. cellenONE is a high-precision image-based single cell sorting and isolation instrument which also enables precision dispensing (pL to µL), allowing sample preparation protocols for a wide range of applications (genomics, transcriptomics, proteomics...). It is also a game changer in the field of cell line development for various applications (monoclonal antibodies, CRISPR-Cas9, stem cell research...). spheroONE is a single spheroid / organoid / tumoroid sorting and dispensing instrument which brings high reproducibility in drug testing and enhances 3D biology research. With these two instruments, we enable image-based isolation of any cell type or cell aggregate from 0.5 - 600 µm, with up to 100% single-particle isolation and outstanding cell viability.
Terence is an Applications Scientist at Namocell, where he works with scientists to accelerate a wide range of single-cell workflows using Namocell’s single-cell technology. Terence has more than 6 years of research and development experience within the academic setting. He holds a PhD in Biomedical Engineering from Cornell University, where he applied his diverse expertise in cell/molecular biology and engineering to develop biologically based regenerative strategies to diagnose and prevent adult cardiovascular disease.
Siddharth Dey is an Assistant Professor in the Department of Chemical Engineering, Center for Bioengineering and Neuroscience Research Institute at the University of California, Santa Barbara. He received his Ph.D. from the University of California, Berkeley in 2012 working with Professor David Schaffer and Professor Adam Arkin. Thereafter, he conducted post-doctoral research in Professor Alexander van Oudenaarden's group at the Hubrecht Institute, The Netherlands before moving to the University of California, Santa Barbara in 2017. Dr. Dey’s group is funded by several NIH R01 grants that support their work developing single-cell sequencing technologies to study how variability in the epigenome regulates gene expression heterogeneity and cell fate decisions during mammalian development.
Matt Davis PhD joined Gritstone Oncology (NASDAQ: GRTS) in 2015 and is currently the Director of Molecular Biology and Sequencing responsible for various neo-antigen discovery and translational genomics efforts. Prior to Gritstone, Dr. Davis conducted post-doctoral research at Warp Drive Bio in the discovery biology group. He holds a PhD in Genetics from Yale with thesis research under the supervision of Dr. Joseph Schlessinger and previous to his graduate work he conducted cancer genomics research at Dana Farber Cancer Institute and the Broad Institute.
John Batts serves as one of the Senior Technical Trainers for Masterflex Bioprocessing. With a life science focused career spanning nearly 30 years, John is passionate about helping customers overcome fluidic challenges through a combination of technical guidance and the application of industry-leading technology. He currently resides in the Pacific Northwest region of the United States with his wife.
Dr. Bryan Bell began his research career at University of Washington before completing his graduate work in molecular biology and biochemistry at University of California, Irvine. He returned to Seattle for his post-doctoral work at Benaroya Research Institute, studying CD4+ T cell responses in allergy models. For the past 9 years, he has held several roles at Takara Bio USA, and is currently the Senior Market Strategy Manager for Biomarker Discovery.
